JP2015501155A5 - - Google Patents

Download PDF

Info

Publication number
JP2015501155A5
JP2015501155A5 JP2014539019A JP2014539019A JP2015501155A5 JP 2015501155 A5 JP2015501155 A5 JP 2015501155A5 JP 2014539019 A JP2014539019 A JP 2014539019A JP 2014539019 A JP2014539019 A JP 2014539019A JP 2015501155 A5 JP2015501155 A5 JP 2015501155A5
Authority
JP
Japan
Prior art keywords
wing segment
modified oligonucleotide
modified
linked nucleosides
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014539019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015501155A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/061984 external-priority patent/WO2013063313A1/en
Publication of JP2015501155A publication Critical patent/JP2015501155A/ja
Publication of JP2015501155A5 publication Critical patent/JP2015501155A5/ja
Pending legal-status Critical Current

Links

JP2014539019A 2011-10-25 2012-10-25 Ｇｃｃｒ発現のアンチセンス調整 Pending JP2015501155A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161551378P 2011-10-25 2011-10-25
US61/551,378 2011-10-25
PCT/US2012/061984 WO2013063313A1 (en) 2011-10-25 2012-10-25 Antisense modulation of gccr expression

Publications (2)

Publication Number Publication Date
JP2015501155A JP2015501155A (ja) 2015-01-15
JP2015501155A5 true JP2015501155A5 (https=) 2015-12-10

Family

ID=48168513

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014539019A Pending JP2015501155A (ja) 2011-10-25 2012-10-25 Ｇｃｃｒ発現のアンチセンス調整

Country Status (14)

Country Link
US (2) US8901098B2 (https=)
EP (1) EP2771463A4 (https=)
JP (1) JP2015501155A (https=)
KR (1) KR20140084232A (https=)
CN (1) CN103906838A (https=)
AU (2) AU2012328680A1 (https=)
BR (1) BR112014009790A2 (https=)
CA (1) CA2853373A1 (https=)
HK (1) HK1201555A1 (https=)
IL (1) IL232183A0 (https=)
IN (1) IN2014CN03749A (https=)
MX (1) MX350944B (https=)
RU (1) RU2014119787A (https=)
WO (1) WO2013063313A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2992098T3 (da) 2013-05-01 2019-06-17 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
BR112016022742B1 (pt) 2014-05-01 2022-06-14 Ionis Pharmaceuticals, Inc Composto químico, composição compreendendo o composto e uso dos mesmos
WO2015179693A1 (en) 2014-05-22 2015-11-26 Isis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
RS60230B1 (sr) * 2015-04-16 2020-06-30 Ionis Pharmaceuticals Inc Kompozicije za moduliranje ekspresije c9orf72
CN108026529A (zh) * 2015-09-30 2018-05-11 Ionis制药公司 组合疗法
US10083668B2 (en) 2016-03-09 2018-09-25 Semiconductor Energy Laboratory Co., Ltd. Semiconductor device, display device, and electronic device
CA3043768A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
UA128786C2 (uk) 2017-10-20 2024-10-23 Дайсерна Фармасьютикалз, Інк Олігонуклеотид для лікування інфекції гепатиту в
KR20200109311A (ko) 2018-01-16 2020-09-22 다이서나 파마수이티컬, 인크. Aldh2 발현을 억제하기 위한 조성물 및 방법
EP3908661A1 (en) 2019-02-12 2021-11-17 Dicerna Pharmaceuticals, Inc. Methods and compositions for inhibiting expression of cyp27a1
CN109680095A (zh) * 2019-02-25 2019-04-26 广西中医药大学 一种鉴定苦玄参品种的ssr引物组合物及其品种鉴定方法
BR112021019793A2 (pt) 2019-04-04 2021-12-07 Dicerna Pharmaceuticals Inc Composições e métodos para inibir expressão de gene no sistema nervoso central
US20230287425A1 (en) 2020-03-18 2023-09-14 Dicerna Pharmacuticals Inc. Compositions and methods for inhibiting angptl3 expression
CA3190481A1 (en) 2020-08-04 2022-02-10 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting plp1 expression
TW202221120A (zh) 2020-08-04 2022-06-01 美商黛瑟納製藥公司 用於治療代謝症候群之組成物及方法
KR20230061389A (ko) 2020-08-04 2023-05-08 다이서나 파마수이티컬, 인크. 올리고뉴클레오티드의 전신 전달
US12435336B2 (en) 2020-08-05 2025-10-07 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting LPA expression
EP4225919A1 (en) 2020-10-08 2023-08-16 Dicerna Pharmaceuticals, Inc. Selective delivery of oligonucleotides to glial cells
PE20250400A1 (es) 2021-04-12 2025-02-11 Dicerna Pharmaceuticals Inc Composiciones y metodos para inhibir cetohexoquinasa
CA3209418A1 (en) 2021-04-14 2022-10-20 Utsav SAXENA Compositions and methods for modulating pnpla3 expression
WO2022223515A2 (en) 2021-04-19 2022-10-27 Novo Nordisk A/S Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression
EP4347820A1 (en) 2021-05-28 2024-04-10 Novo Nordisk A/S Compositions and methods for inhibiting mitochondria amidoxime reducing component 1 (marc1) expression
EP4392556A1 (en) 2021-08-25 2024-07-03 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting ?lpha-1 antitrypsin expression
JP2024543195A (ja) 2021-12-01 2024-11-19 ディセルナ ファーマシューティカルズ インコーポレイテッド Ａｐｏｃ３発現を調節するための組成物及び方法
US20230374522A1 (en) 2022-04-15 2023-11-23 Dicerna Pharmaceuticals, Inc. Compositions and methods for modulating scap activity
CN119173631A (zh) 2022-05-12 2024-12-20 迪克纳制药公司 用于抑制mapt表达的组合物和方法
IL316843A (en) 2022-05-13 2025-01-01 Dicerna Pharmaceuticals Inc Compounds and methods for inhibiting SNCA deactivation
TWI868755B (zh) 2022-06-24 2025-01-01 丹麥商諾佛 儂迪克股份有限公司 抑制跨膜絲胺酸蛋白酶６（ｔｍｐｒｓｓ６）表現的組成物及方法
TW202430637A (zh) 2022-11-16 2024-08-01 美商戴瑟納製藥股份有限公司 Stat3靶向性寡核苷酸及其用途
IL326017A (en) 2023-07-28 2026-03-01 Novo Nordisk As Compositions and methods for expressing programmed death ligand receptor (PD-L1)

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
WO1988000975A1 (en) 1986-08-01 1988-02-11 Genetics Institute, Inc. High level inducible expression of heterologous genes
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5227170A (en) 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5527528A (en) 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
JP3220180B2 (ja) 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
US5985558A (en) 1997-04-14 1999-11-16 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
US5872242A (en) 1992-10-05 1999-02-16 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of ras
US5583020A (en) 1992-11-24 1996-12-10 Ribozyme Pharmaceuticals, Inc. Permeability enhancers for negatively charged polynucleotides
JPH08504559A (ja) 1992-12-14 1996-05-14 ハネウエル・インコーポレーテッド 個別に制御される冗長巻線を有するモータシステム
JP3351476B2 (ja) 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5462854A (en) 1993-04-19 1995-10-31 Beckman Instruments, Inc. Inverse linkage oligonucleotides for chemical and enzymatic processes
US5534259A (en) 1993-07-08 1996-07-09 Liposome Technology, Inc. Polymer compound and coated particle composition
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5591721A (en) 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
US5512295A (en) 1994-11-10 1996-04-30 The Board Of Trustees Of The Leland Stanford Junior University Synthetic liposomes for enhanced uptake and delivery
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
US6133246A (en) 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US5877309A (en) 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
JP4236812B2 (ja) 1997-09-12 2009-03-11 エクシコン エ／エス オリゴヌクレオチド類似体
WO1999015643A2 (en) 1997-09-25 1999-04-01 University Of Florida ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO ANGIOTENSI N CONVERTING ENZYME mRNA AND METHODS OF USE
US20030203862A1 (en) 1998-03-26 2003-10-30 Miraglia Loren J. Antisense modulation of MDM2 expression
US6238921B1 (en) 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
US20030228597A1 (en) 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
US6821724B1 (en) 1998-09-17 2004-11-23 Affymetrix, Inc. Methods of genetic analysis using nucleic acid arrays
US6228642B1 (en) 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
JP4785252B2 (ja) 1999-02-26 2011-10-05 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア Ｔｒｐｍ−２アンチセンス療法
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
GB9907048D0 (en) 1999-03-27 1999-05-19 Karobio Ab Novel glucocorticoid receptor ligands for the treatment of meta bolic disorders
US7053207B2 (en) 1999-05-04 2006-05-30 Exiqon A/S L-ribo-LNA analogues
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
CA2393045A1 (en) 1999-12-07 2001-06-14 Sumitomo Chemical Co., Ltd. Mutant er.alpha. and test systems for transactivation
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
GB0008936D0 (en) 2000-04-11 2000-05-31 Glaxo Group Ltd Vectors
US6649341B1 (en) 2000-04-19 2003-11-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Human glucocorticoid receptor 1A promoter and splice variants
US6656700B2 (en) 2000-05-26 2003-12-02 Amersham Plc Isoforms of human pregnancy-associated protein-E
US7227007B2 (en) 2000-12-28 2007-06-05 Asahi Kasei Pharma Corporation NF-κB activating gene
WO2003008583A2 (en) 2001-03-02 2003-01-30 Sagres Discovery Novel compositions and methods for cancer
WO2003070887A2 (en) 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2002096943A1 (en) 2001-05-25 2002-12-05 Asahi Kasei Kabushiki Kaisha Stat6-activating genes
US20030092616A1 (en) 2001-05-25 2003-05-15 Akio Matsuda STAT6 activation gene
CA2452458A1 (en) 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
JP2005516586A (ja) 2001-07-20 2005-06-09 ボード オブ トラスティーズ オブ ザ ユニヴァースティ オブ イリノイ 癌の処置に対する遺伝子標的を同定するための試薬および方法
US7425545B2 (en) 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
US20060088828A1 (en) 2002-01-23 2006-04-27 Harris Peter C Polycystic kidney disease nucleic acids and proteins
AU2003213057A1 (en) 2002-02-20 2003-09-09 Ribozyme Pharmaceuticals, Incoporated Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid
JP2003265184A (ja) 2002-03-18 2003-09-24 Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho 被検者におけるグルココルチコイド製剤の有効性の検査方法
AU2003219432B2 (en) 2002-03-27 2010-04-01 Pharmascience Inc. Antisense IAP nucleobase oligomers and uses thereof
AU2003225495B2 (en) 2002-04-05 2009-01-15 Roche Innovation Center Copenhagen A/S Oligomeric compounds for the modulation HIF-1alpha expression
WO2003099215A2 (en) 2002-05-20 2003-12-04 Pharmacia Corporation Antisense modulation of glucocorticoid receptor expression
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
CN100558740C (zh) 2002-08-16 2009-11-11 雷克珊公司 反义寡核苷酸用于抑制Akt-1表达的用途
AU2003298556A1 (en) 2002-08-19 2004-05-04 Regulome Corporation Functional sites
SI1530636T1 (sl) 2002-08-21 2010-12-31 Stry Liaison Ofiice The University Of British Columbia Umiversity Indu Zdravljenje melanoma z zniĹľanjem nivojev klusterina
AU2003291755A1 (en) 2002-11-05 2004-06-07 Isis Pharmaceuticals, Inc. Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
WO2004041889A2 (en) 2002-11-05 2004-05-21 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
AU2003295600A1 (en) 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
JP2006506991A (ja) 2002-11-25 2006-03-02 デン・コンゲリエ・ヴェテリネー−オ・ランボホイスコレ ブタ多型およびその検出のための方法
WO2004094636A1 (en) 2003-04-24 2004-11-04 Galapagos Genomics N.V. Effective sirna knock-down constructs
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
EP1661905B9 (en) 2003-08-28 2012-12-19 IMANISHI, Takeshi Novel artificial nucleic acids of n-o bond crosslinkage type
US20050142581A1 (en) 2003-09-04 2005-06-30 Griffey Richard H. Microrna as ligands and target molecules
US20050074801A1 (en) 2003-09-09 2005-04-07 Monia Brett P. Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
US20050053981A1 (en) 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
CA2538252C (en) 2003-09-18 2014-02-25 Isis Pharmaceuticals, Inc. 4'-thionucleosides and oligomeric compounds
US20070009899A1 (en) 2003-10-02 2007-01-11 Mounts William M Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
WO2005061710A1 (en) 2003-12-23 2005-07-07 Santaris Pharma A/S Oligomeric compounds for the modulation of bcl-2
EP1711606A2 (en) 2004-01-20 2006-10-18 Isis Pharmaceuticals, Inc. Modulation of glucocorticoid receptor expression
US7919472B2 (en) 2004-09-17 2011-04-05 Isis Pharmaceuticals, Inc. Enhanced antisense oligonucleotides
US20070154896A1 (en) 2005-02-11 2007-07-05 International Business Machines Corporation System and method for identification of MicroRNA target sites and corresponding targeting MicroRNA sequences
JP2006320271A (ja) * 2005-05-20 2006-11-30 Tokyo Institute Of Technology 低分子化合物とタンパク質の結合評価方法
KR20080065617A (ko) * 2005-09-19 2008-07-14 존슨 앤드 존슨 파머슈티컬 리서치 앤드 디벨로프먼트 엘엘씨 글루코코티코이드 수용체 발현의 조절
WO2007090071A2 (en) 2006-01-27 2007-08-09 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
JP2009536222A (ja) 2006-05-05 2009-10-08 アイシス ファーマシューティカルズ， インコーポレーテッド Ｐｃｓｋ９の発現を調節するための化合物および方法
AU2007249349B2 (en) 2006-05-11 2012-03-08 Isis Pharmaceuticals, Inc. 5'-Modified bicyclic nucleic acid analogs
WO2008101157A1 (en) 2007-02-15 2008-08-21 Isis Pharmaceuticals, Inc. 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
CA2688321A1 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
DK2173760T4 (en) 2007-06-08 2016-02-08 Isis Pharmaceuticals Inc Carbocyclic bicyclic nukleinsyreanaloge
AU2008272918B2 (en) 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs

Similar Documents

Publication Publication Date Title
JP2015501155A5 (https=)
JP2014530004A5 (https=)
JP2014511686A5 (https=)
IL264288B (en) Methods and compositions for modulating apolipoprotein(a) expression
JP2014513954A5 (https=)
JP2014521310A5 (https=)
JP2016501513A5 (https=)
NL300963I9 (nl) Een verbinding omvattende een gemodificeerd oligonucleotide met een nucleobasensequentie bestaande uit 20 gekoppelde nucleosiden volgens EP-B1-2563920 conclusie 1 (SEQ ID NO: 80), waarbij de gemodificeerde oligonucleotide omvat: een tussenruimtesegment dat bestaat uit tien gekoppelde deoxynucleosiden; een 5' vleugelsegment dat bestaat uit vijf gekoppelde nucleosiden; en een 3' vleugelsegment dat bestaat uit vijf gekoppelde nucleosiden; waarbij het tussenruimtesegment is gepositioneerd tussen het 5' vleugelsegment en het 3' vleugelsegment, waarbij elke nucleoside van elk vleugelsegment een 2'-O-methoxyethylsuiker omvat; waarbij elke cytosine van het gemodificeerde oligonucleotide een 5-methylcytosine is, en waarbij elke internucleosidekoppeling van het gemodificeerde oligonucleotide een fosforothioaatkoppeling is; en in het bijzonder inotersen; en derivaten daarvan, zoals zouten ervan, waaronder natriumzouten, zoals beschermd door EP-B1-2563920.
JP2013516489A5 (https=)
HRP20210244T1 (hr) Moduliranje eksprimiranja virusa hepatitisa b (hbv)
JP2015507625A5 (https=)
JP2017510271A5 (https=)
JP2011501962A5 (https=)
JP2010507579A5 (https=)
RU2016116849A (ru) Композиции для модуляции экспрессии c90rf72
IL261901A (en) Compositions and methods for modulating apolipoprotein expression
FI2906696T4 (fi) Menetelmiä c9orf72:n ilmentymisen moduloimiseksi
JP2017505116A5 (https=)
JP2012050438A5 (https=)
JP2016116520A5 (https=)
JP2015536132A5 (https=)
RU2016130110A (ru) Способы хирургической обработки путем резания и сшивания скобками
RU2011119479A (ru) Модуляция экспрессии фактора 11
RU2016129725A (ru) Модуляция экспрессии ангиопоэтин-подобного белка 3
RU2014115215A (ru) Антисмысловая регуляция экспрессии gcgr